How should anemia of prematurity be managed in a preterm infant (<32 weeks gestation or <1500 g), including transfusion thresholds, iron supplementation, and erythropoietin therapy?

Management of Anemia of Prematurity in Preterm Infants <32 Weeks or <1500g

Use a restrictive red blood cell transfusion strategy with hemoglobin thresholds that vary by postnatal age and respiratory support status, as this approach has moderate certainty evidence showing no difference in mortality or neurodevelopmental outcomes compared to liberal strategies. 1

Red Blood Cell Transfusion Thresholds

The 2024 JAMA Network Open guideline, based on systematic review of 6 RCTs with 3,483 participants, provides specific hemoglobin-based transfusion thresholds 1:

For Infants on Respiratory Support

(Defined as invasive mechanical ventilation, CPAP, NIPPV, or nasal cannula ≥1 L/min)

• Postnatal week 1: Transfuse at hemoglobin <11 g/dL 1
• Postnatal week 2: Transfuse at hemoglobin <10 g/dL 1
• Postnatal week 3 and beyond: Transfuse at hemoglobin <9 g/dL 1

For Infants on No or Minimal Respiratory Support

• Postnatal week 1: Transfuse at hemoglobin <10 g/dL 1
• Postnatal week 2: Transfuse at hemoglobin <8.5 g/dL 1
• Postnatal week 3 and beyond: Transfuse at hemoglobin <7 g/dL 1

These restrictive thresholds showed no increased risk of death, bronchopulmonary dysplasia, severe intraventricular hemorrhage, necrotizing enterocolitis, severe retinopathy of prematurity, or death/neurodevelopmental impairment at 2 years compared to higher thresholds. 1

Transfusion Volume and Administration

When transfusion is indicated, administer 15-20 mL/kg of packed red blood cells over 3-4 hours 1. The TOP trial used 15 mL/kg while the ETTNO trial used 20 mL/kg, both with similar outcomes 1.

Iron Supplementation

Begin enteral iron supplementation at 2-6 mg/kg/day once the infant tolerates at least 50% of energy intake enterally, typically starting around day 14 of life. 2, 3

• Target ferritin levels >100 ng/mL when using erythropoietin therapy 4
• Early iron supplementation (starting day 14) combined with erythropoietin is safe and does not increase risk of necrotizing enterocolitis, intraventricular hemorrhage, or retinopathy of prematurity 2
• Many clinicians withhold iron supplementation temporarily after red blood cell transfusions due to concerns about iron overload, though evidence for this practice is limited 1
• Each 15 mL/kg transfusion provides approximately 8-12 mg/kg of iron, though most is not bioavailable until transfused erythrocytes are broken down after 60-70 days 1

Erythropoietin Therapy

Erythropoietin therapy is NOT recommended for routine prevention of early transfusions in very low birth weight infants, but may be considered for infants <1000g to reduce late transfusions after the second week of life. 5, 4

Evidence Against Routine Use

• Large multicenter trials demonstrate that erythropoietin cannot prevent early transfusions, particularly in very low birth weight infants with severe neonatal diseases 4
• The primary benefit is reducing late transfusions and potentially decreasing donor exposure rather than eliminating transfusions entirely 4

If Erythropoietin is Used (Limited Indications)

Restrict use to:

• Infants <1000g birth weight, OR
• Infants 1000-1250g with risk factors for transfusion (severe initial disease) 4

Dosing regimen:

• Start at 3-7 days of life 4
• Dose: 250 U/kg subcutaneously three times weekly 4, or 500 U/kg twice weekly 3
• Duration: 4-6 weeks depending on gestational age 4
• Must be combined with oral iron 2-12 mg/kg/day to maintain ferritin >100 ng/mL 4

Outcomes with Erythropoietin

Studies show erythropoietin combined with early iron supplementation:

• Increases reticulocyte counts and final hematocrit levels 3
• Reduces transfusion volume and number of transfusions in infants <1000g 2
• Has no effect on severe retinopathy of prematurity, intraventricular hemorrhage, necrotizing enterocolitis, or bronchopulmonary dysplasia 2

Strategies to Minimize Transfusion Need

Implement blood conservation strategies from birth:

• Delayed umbilical cord clamping (30-60 seconds) to maximize placental transfusion 6
• Minimize phlebotomy losses, especially during the first 72 hours of life 6
• Use non-invasive monitoring techniques when possible 5
• Ensure adequate nutritional support to promote erythropoiesis 4

The combination of delayed cord clamping, fewer phlebotomies, erythropoietin, and parenteral iron in high-altitude settings reduced transfusion needs from 32% to 9% over a 10-year period 6.

Common Pitfalls to Avoid

• Do not use liberal transfusion thresholds thinking they improve outcomes—moderate certainty evidence shows no benefit for mortality or neurodevelopmental impairment 1
• Do not start erythropoietin without adequate iron supplementation—this will result in iron-limited erythropoiesis and treatment failure 4
• Do not expect erythropoietin to prevent early transfusions in the first 2 weeks of life, particularly in extremely low birth weight infants 5, 4
• Do not transfuse based solely on hemoglobin level—consider respiratory support needs and postnatal age using the algorithm above 1

Monitoring and Follow-up

• Monitor complete blood count and reticulocyte count weekly during active management 3
• Track all phlebotomy losses to identify excessive blood draws 5
• Continue monitoring hemoglobin levels after discharge, as anemia of prematurity can persist for months 7
• Assess for signs of progressive anemia: poor weight gain, feeding intolerance, tachycardia, increased apnea/bradycardia events 8